Parnaparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Parnaparin
Accession Number
DB09260
Type
Small Molecule
Groups
Approved, Investigational
Description

Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Synonyms
  • Parnaparin sodium
Categories
UNII
M316WT19D8
CAS number
9005-49-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(1,2,6,7-3H)TestosteroneThe therapeutic efficacy of Parnaparin can be increased when used in combination with (1,2,6,7-3H)Testosterone.
(R)-warfarinThe risk or severity of bleeding can be increased when Parnaparin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Parnaparin is combined with (S)-Warfarin.
1-TestosteroneThe therapeutic efficacy of Parnaparin can be increased when used in combination with 1-Testosterone.
18-methyl-19-nortestosteroneThe therapeutic efficacy of Parnaparin can be increased when used in combination with 18-methyl-19-nortestosterone.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Parnaparin is combined with 4-hydroxycoumarin.
4-HydroxytestosteroneThe therapeutic efficacy of Parnaparin can be increased when used in combination with 4-Hydroxytestosterone.
5beta-dihydrotestosteroneThe therapeutic efficacy of Parnaparin can be increased when used in combination with 5beta-dihydrotestosterone.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Parnaparin.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Parnaparin.
Food Interactions
Not Available

References

General References
  1. Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C: Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost. 2007 Jun;97(6):965-73. [PubMed:17549299]
External Links
PubChem Substance
347910424
Wikipedia
Parnaparin
ATC Codes
B01AB07 — Parnaparin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentInfertilities / Low Molecular Weight Heparin1
3TerminatedTreatmentRetinal Vein Occlusions(RVO)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 11:08 / Updated on November 02, 2018 07:00